Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Starpharma Holdings Limited ( (AU:SPL) ) has issued an announcement.
Starpharma Holdings Limited has announced a significant collaboration and license agreement with Genentech, part of the Roche Group. This partnership will leverage Starpharma’s DEP® platform to develop dendrimer-drug conjugates targeting specific oncology areas. The agreement includes an upfront payment of USD $5.5 million, with potential success-based milestones totaling up to USD $564 million. Additionally, Starpharma stands to earn tiered royalties on the global net sales of any resulting products, marking a substantial opportunity for growth and industry positioning.
More about Starpharma Holdings Limited
Starpharma Holdings Limited operates in the biotechnology industry, focusing on the development of dendrimer-based products. The company is known for its proprietary DEP® platform technology, which is used to create dendrimer-drug conjugates for various medical applications, particularly in oncology.
YTD Price Performance: 18.18%
Average Trading Volume: 318,370
Technical Sentiment Signal: Hold
Current Market Cap: A$54.37M
For an in-depth examination of SPL stock, go to TipRanks’ Overview page.